The number of antibody doses and time needed to achieve complete response and tumor elimination was reduced when using multiple ICB and anti-TREM2 compared to anti-PD-1 alone (Figure 4 J), limiting mice exposure to potential chronic adverse events. This evidence concerns the gene PDCD1 and neoplasm.